Nary a day goes by that the plaintiffs’ bar is not busily at work initiating a new mass tort action. Some cases expand on ...

UK pharmaceutical giant GSK says it will pay as much as $2.2bn (£1.68bn) to settle thousands of cases in US courts over claims that a discontinued version of its heartburn drug Zantac caused cancer.

GSK and other drugmakers fending off litigation claiming that gastrointestinal drug Zantac or a generic caused cancer have won a supreme court ruling in Canada, after also chalking up wins in the US.

In September 2019, the FDA announced that a small amount of cancer-causing chemicals, known as N-Nitrosodimethylamine (NDMA), were found in certain heartburn medications, such as Zantac.

葛兰素史克 在美国州法院Zantac案件中达成高达22亿美元的和解协议。 葛兰素史克公司周三表示，已与10家原告公司达成协议，这些公司占美国州法院 ...

Operating profit at GSK fell by 86 per cent due to a charge related to the settlement of Zantac settlements the company said ...

“This [whistleblower] case is not about whether the NDMA in ranitidine causes cancer. … That issue is at the heart of personal injury lawsuits related to ranitidine causing individual consumers cancer ...

Shares in pharmaceutical company GlaxoSmithKline (GSK) surged more than 6% after the company revealed it had reached a settlement of up to $2.2bn (€2.01bn) to end tens of thousands of lawsuits ...

GSK earlier this month agreed to pay $2.3 billion to end lawsuits alleging that Zantac caused cancer, despite the group not admitting liability. Stripping out the litigation costs, GSK said ...

Cancer fatalism-the belief that death is inevitable when cancer is present-has been identified as a barrier to participation in cancer screening, detection, and treatment. Yet this literature has ...

Get detailed information on Ranitidine, including pronunciation, uses, dosage guidelines, indications, and instructions on how and when to take it and when to avoid it. The updated prescription ...